相互作用
Exenatide injectable + Insulin glargine-lixisenatide
重症度: 重大
Exenatide injectable and Insulin glargine-lixisenatide: major interaction.
最終更新日
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
概要
Both products are GLP-1 receptor agonists (lixisenatide in the fixed-dose combination and exenatide), so combining them duplicates therapy without a proven added benefit. Gastrointestinal adverse effects, and hypoglycemia from the insulin component, may be increased.
この相互作用をわかりやすく説明すると
Exenatide injectable and Insulin glargine-lixisenatide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
なぜ起こるのか
Duplicate GLP-1 receptor agonist activity producing additive pharmacodynamic effects on insulin secretion, gastric emptying and appetite.
対処法
Avoid using two GLP-1 receptor agonists together; choose a single agent and stop the duplicate. If the combination is unavoidable, monitor blood glucose and GI tolerability closely and reduce insulin as needed.
薬剤師に尋ねること
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Exenatide injectableとInsulin glargine-lixisenatideの臨床対応の詳細なアドバイス、追加の注記、エビデンスの詳細、処方全体を対象とした相互作用チェッカーを利用できます。
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
WebでPro+を14日間無料でお試し。カード登録不要。
Insulin glargine-lixisenatideのその他の相互作用
よくある質問
Can I take Exenatide injectable with Insulin glargine-lixisenatide?
MediHelp rates the interaction as major. Exenatide injectable and Insulin glargine-lixisenatide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both products are GLP-1 receptor agonists (lixisenatide in the fixed-dose combination and exenatide), so combining them duplicates therapy without a proven added benefit. Gastrointestinal adverse effects, and hypoglycemia from the insulin component, may be increased.
How serious is the interaction between Exenatide injectable and Insulin glargine-lixisenatide?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid using two GLP-1 receptor agonists together; choose a single agent and stop the duplicate. If the combination is unavoidable, monitor blood glucose and GI tolerability closely and reduce insulin as needed.
What other medicines interact with Insulin glargine-lixisenatide?
MediHelp also lists interactions of Insulin glargine-lixisenatide with, for example, Albiglutide, Chlorpropamide, Dulaglutide. The full list is on the Insulin glargine-lixisenatide page.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
